Trials / Completed
CompletedNCT05638282
A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Subcutaneous Doses of Cendakimab in Chinese Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the drug levels, safety, and tolerability of cendakimab in healthy male and female Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cendakimab | Specified dose on specified days |
| DRUG | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2023-02-15
- Primary completion
- 2023-06-27
- Completion
- 2023-06-27
- First posted
- 2022-12-06
- Last updated
- 2023-08-01
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05638282. Inclusion in this directory is not an endorsement.